Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of antica...
Saved in:
Main Authors: | Tomi Hendrayana (Author), André Wilmer (Author), Verena Kurth (Author), Ingo GH Schmidt-Wolf (Author), Ulrich Jaehde (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2017-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
by: Zhao D, et al.
Published: (2022) -
Polymyxin B in Patients With Renal Impairment: Is It Necessary to Adjust Dose?
by: Ruifang Nie, et al.
Published: (2022) -
Antimicrobial dose adjustment by renal function in adult Intensive Care Unit
by: Camila Schafer ROJAS, et al.
Published: (2023) -
Inappropriate Doses of Intravenous Polymyxin B after Renal Adjustment Lead to Treatment Failure
by: Bahiah Ismail, et al.
Published: (2021) -
Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
by: Junzhen Wu, et al.
Published: (2023)